Carson Wealth (CWM LLC)
RVNC

Carson Wealth (CWM LLC)’s Revance Therapeutics, Inc. RVNC Stock Holding History

Carson Wealth (CWM LLC)’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,432
Closed -$17K – 5273
2024
Q4 		$17K Sell
5,432
-3,262
-38% -$14.2K ﹤0.01% 3562
2024
Q3 		$45K Buy
8,694
+7,304
+525% +$36.3K ﹤0.01% 2776
2024
Q2 		$4K Buy
1,390
+541
+64% +$1.85K ﹤0.01% 4022
2024
Q1 		$4K Buy
849
+653
+333% +$3.87K ﹤0.01% 3808
2023
Q4 		$2K Buy
196
+151
+336% +$1.24K ﹤0.01% 3864
2023
Q3 		$1K Sell
45
-128
-74% -$2.46K ﹤0.01% 4118
2023
Q2 		$4K Sell
173
-12
-6% -$374 ﹤0.01% 3582
2023
Q1 		$6K Sell
185
-7
-4% -$218 ﹤0.01% 3249
2022
Q4 		$4K Buy
192
+36
+23% +$823 ﹤0.01% 3352
2022
Q3 		$4K Hold
156
– – ﹤0.01% 3240
2022
Q2 		$2K Buy
156
+32
+26% +$493 ﹤0.01% 3444
2022
Q1 		$2K Buy
124
+91
+276% +$1.38K ﹤0.01% 3262
2021
Q4 		$1K Buy
+33
New +$550 ﹤0.01% 3416

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Carson Wealth (CWM LLC)'s RVNC Position: Q1 2025 in Review

Carson Wealth (CWM LLC) sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 5,432 shares — an estimated $17K sold.

Carson Wealth (CWM LLC) first reported a position in RVNC in Q4 2021 and held it in 13 quarters. The position peaked at $45K in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Carson Wealth (CWM LLC) reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Carson Wealth (CWM LLC) sold 5,432 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $17K.
  • Carson Wealth (CWM LLC) first reported a position in Revance Therapeutics, Inc. in Q4 2021 and held it in 13 quarters.
  • Carson Wealth (CWM LLC)'s Revance Therapeutics, Inc. position peaked at $45K in Q3 2024.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Carson Wealth (CWM LLC)'s 13F filing for Q1 2025, filed 1 May 2025.